PARIS, France I February 12, 2025 I GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and ...
LONDON, UK I 11, 2025 I Ellipses Pharma Limited (“Ellipses”), a global drug development company focused on accelerating the development of cancer ...
Safety Study of Stem Cell-derived Transplant Includes Subacute and Chronic SCI Patients. CARLSBAD, CA, USA I 11, 2025 I Lineage Cell Therapeutics, Inc. (NYSE American and ...
Collaboration builds on Alloy’s existing and highly productive engagement with Pfizer and will apply Alloy’s innovation expertise to address Pfizer’s specific ...
JERSEY CITY, NJ, USA I January 30, 2025 I Celltrion today announced that the U.S. Food and Drug Administration (FDA) has approved AVTOZMA® (CT-P47, ...
Lion TCR announced that its mRNA-encoded T-cell receptor (TCR)-T cell therapy product Liocyx-M004 has received clearance from the U.S. Food and Drug Administration (FDA) to initiate an international ...
(NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the Biologics License Application (BLA) for linvoseltamab for the treatment ...
PALO ALTO, CA, USA I February 11, 2025 I BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused ...
Company plans to initiate a Phase 1/b trial in relapsed/refractory, locally advanced/metastatic bladder cancer by year-end ...
BASEL, Switzerland I 11, 2025 I Novartis today announced that it has entered into an agreement to acquire Anthos Therapeutics, Inc., a Boston-based, ...
INGELHEIM, Germany I 10, 2025 I Boehringer Ingelheim announced today that the FIBRONEER™-ILD trial met its primary endpoint, which was the ...
RALEIGH, NC, USA I 10, 2025 I Accord BioPharma, Inc., the U.S. specialty division of Intas Pharmaceuticals, Ltd. ("Intas ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback